Prevention of coronary heart disease in primary medical care in Poland: Results from the LIPIDOGRAM study

European Journal of Preventive Cardiology

Volumn 18, Issue 2, 2011, Pages 287-296

  Tomasik, Tomasz ^a   Jozwiak, Jacek ^b,c   Windak, Adam ^a   Rygiel, Katarzyna ^b   Mastej, Miroslaw ^c   Smithson, W Henry ^d   Mathers, Nigel ^d   Tomaszewski, Maciej ^e   Kaess, Bernhard M ^f   Tykarski, Andrzej ^g   Konduracka, Ewa ^a   Grzeszczak, Wladyslaw ^h   Lukas, Witold ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b CZESTOCHOWA UNIVERSITY OF TECHNOLOGY   (Poland)

^c Silesian Analytical Laboratories   (Poland)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f UNIVERSITY OF REGENSBURG   (Germany)

^g POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^h MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Cross sectional study; hypercholesterolaemia prevention; pharmacotherapy; primary health care

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DEMOGRAPHY; FEMALE; HEALTH PROGRAM; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POLAND; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE;

AGED; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; HYPERCHOLESTEROLEMIA; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; POLAND; PRACTICE GUIDELINES AS TOPIC; PREVENTIVE HEALTH SERVICES; PRIMARY HEALTH CARE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 79959203371     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/1741826710389366     Document Type: Article

References (22)

1. O’Keefe JH, Carter MD, Lavie CJ. Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc 2009; 84(8): 741–757.
2. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008; 52(22): 1769–1781.
3. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8(5): 453–463.
4. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R Committee for Practice Guidelines ESC. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14(Suppl 2): E1–E40.
5. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004; 24(8): e149–e161.
6. Ferrières J, Gousse ET, Fabry C, Hermans MP French CEPHEUS Investigators. Assessment of lipid-lowering treatment in France – the CEPHEUS study. Arch Cardiovasc Dis 2008; 101(9): 557–563.
7. Svilaas A, Strandberg T, Eriksson M, Hildebrandt P, Westheim A. Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia. Scand Cardiovasc J 2008; 42(4): 279–287.
8. Paragh G, Márk L, Zámolyi K, Pados G, Ofner P. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study. Clin Drug Investig 2007; 27(9): 647–660.
9. Jankowski P, Kawecka-Jaszcz K, Pajak A, Bilo G, Dubiel JS, Maciejewicz J, et al. [Cracovian program for secondary prevention of ischemic heart disease. Secondary prevention of ischemic heart disease after discharge in 1997–98 and 1999–2000]. Przegl Lek 2003; 60(3): 142–146 [in Polish].
10. Kotseva K, Stagmo M, De Bacquer D, De Backer G, Wood D EUROASPIRE II Study Group. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis 2008; 197(2): 710–717.
11. Pająk A, Wiercińska E, Polakowska M, Kozakiewicz K, Kaczmarczyk-Chałas K, Tykarski A, et al. Rozpowszechnienie dyslipidemii u mezczyzn i kobiet w wieku 20–74 lat w Polsce. Wyniki programu WOBASZ. [Prevelance of dyslipidemia amoung men and women age 20–74 in Poland]. Kardiol Pol 2005; 63(Suppl. 4): S1–S6 [in Polish].
12. Jozwiak J, Mastej M, Lukas W, Piwowarska W, Konduracka E, Tykarski A, et al. LIPIDOGRAM2004 vs LIPIDOGRAM2006. Czy sytuacja epidemiologiczna w zakresie zaburzeń lipidowych uległa zmianie? [LIPIDOGRAM2004 vs. LIPIDOGRAM2006 study. Has the epidemiological situation in the field of lipid disorders changed?]. Probl Med Rodz 2007; 9(2): 78–81 [in Polish].
13. Kaess BM, Jozwiak J, Mastej M, Lukas W, Grzeszczak W, Windak A, et al. Association between anthropometric obesity measures and coronary artery disease: a cross-sectional survey of 16,657 subjects from 444 Polish cities. Heart 2010; 96(2): 131–135.
14. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373(9667): 929–940.
15. Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005; 21(9): 1389–1399.
16. Geller JC, Cassens S, Brosz M, Keil U, Bernarding J, Kropf S, et al. Achievement of guideline-defined treatment goals in primary care: the German Coronary Risk Management (CoRiMa) study. Eur Heart J 2007; 28(24): 3051–3058.
17. Steinhagen-Thiessen E, Bramlage P, Lösch C, Hauner H, Schunkert H, Vogt A, et al. Dyslipidemia in primary care – prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol 2008; 7: 31–31.
18. Paragh G, Márk L, Zámolyi K, Pados G, Ofner P. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study. Clin Drug Investig 2007; 27(9): 647–660.
19. Waters DD, Brotons C, Chiang CW, Ferrières J, Foody J, Jukema JW, et al Lipid Treatment Assessment Project 2 Investigators. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009; 120(1): 28–34.
20. Stagmo M, Israelsson B, Brandström H, Hedbäck B, Lingfors H, Nilsson P, et al. The Swedish National Programme for Quality Control of Secondary Prevention of Coronary Artery Disease – results after one year. Eur J Cardiovasc Prev Rehabil 2004; 11(1): 18–24.
21. Goldenberg N, Glueck C. Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk. Vasc Health Risk Manag 2009; 5(1): 369–376.
22. Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005; 111(4): 499–510.